Dynavax Technologies

Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024

by

EMERYVILLE, Calif., Feb. 8, 2024 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2023 financial results on Thursday, February 22, 2024, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, … Read more

Dynavax to Present at Upcoming Investor Conferences

by

EMERYVILLE, Calif., May 30, 2023 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6 at 9:20 a.m. CT Goldman Sachs … Read more